NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $168.83 -7.17 (-4.07 %) (As of 03/22/2019 04:00 PM ET)Previous Close$168.83Today's Range$167.2347 - $176.4952-Week Range$90.14 - $182.23Volume538,428 shsAverage Volume562,541 shsMarket Capitalization$5.09 billionP/E Ratio-15.99Dividend YieldN/ABeta2.81 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. Receive GWPH News and Ratings via Email Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GWPH Previous Symbol CUSIPN/A CIK1351288 Webwww.gwpharm.com Phone44-12-2326-6800Debt Debt-to-Equity Ratio0.01 Current Ratio6.66 Quick Ratio6.34Price-To-Earnings Trailing P/E Ratio-15.99 Forward P/E Ratio-21.16 P/E GrowthN/A Sales & Book Value Annual Sales$12.74 million Price / Sales399.68 Cash FlowN/A Price / Cash FlowN/A Book Value$13.76 per share Price / Book12.27Profitability EPS (Most Recent Fiscal Year)($10.56) Net Income$-295,160,000.00 Net Margins-1,734.86% Return on Equity-55.88% Return on Assets-48.65%Miscellaneous EmployeesN/A Outstanding Shares30,160,000Market Cap$5.09 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions What is GW Pharmaceuticals PLC-'s stock symbol? GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH." How were GW Pharmaceuticals PLC-'s earnings last quarter? GW Pharmaceuticals PLC- (NASDAQ:GWPH) announced its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.40) by $1.14. The biopharmaceutical company earned $3.46 million during the quarter, compared to analyst estimates of $2 million. GW Pharmaceuticals PLC- had a negative return on equity of 55.88% and a negative net margin of 1,734.86%. View GW Pharmaceuticals PLC-'s Earnings History. When is GW Pharmaceuticals PLC-'s next earnings date? GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for GW Pharmaceuticals PLC-. What price target have analysts set for GWPH? 11 Wall Street analysts have issued 1-year target prices for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $134.00 to $227.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $179.00 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-. What is the consensus analysts' recommendation for GW Pharmaceuticals PLC-? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-. What are Wall Street analysts saying about GW Pharmaceuticals PLC- stock? Here are some recent quotes from research analysts about GW Pharmaceuticals PLC- stock: 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating on GW Pharmaceuticals and raising our 12-month price target to $196/ADS from $193/ ADS following the announced sale of Voucher (PRV). As a reminder, GW Pharmaceuticals was awarded the PRV following the EPIDIOLEX approval last year. The recipient of the PRV was not announced in the press release." (3/18/2019) 2. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (3/2/2019) Has GW Pharmaceuticals PLC- been receiving favorable news coverage? Press coverage about GWPH stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GW Pharmaceuticals PLC- earned a news impact score of 0.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next several days. Who are some of GW Pharmaceuticals PLC-'s key competitors? Some companies that are related to GW Pharmaceuticals PLC- include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE). What other stocks do shareholders of GW Pharmaceuticals PLC- own? Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Cronos Group (CRON), Cara Therapeutics (CARA), Gilead Sciences (GILD), Celgene (CELG) and Insys Therapeutics (INSY). Who are GW Pharmaceuticals PLC-'s key executives? GW Pharmaceuticals PLC-'s management team includes the folowing people: Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)Mr. Justin D. Gover, CEO & Exec. Director (Age 48)Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)Dr. Volker Knappertz M.D., D.Sc., Chief Medical Officer (Age 54) Who are GW Pharmaceuticals PLC-'s major shareholders? GW Pharmaceuticals PLC-'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Prudential PLC (4.39%), Canada Pension Plan Investment Board (3.90%), BlackRock Inc. (1.82%), Lord Abbett & CO. LLC (1.77%), Jennison Associates LLC (1.71%) and Bank of America Corp DE (1.62%). Company insiders that own GW Pharmaceuticals PLC- stock include Cabot Brown, Catherine J Mackey, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello and Volker Knappertz. View Institutional Ownership Trends for GW Pharmaceuticals PLC-. Which major investors are selling GW Pharmaceuticals PLC- stock? GWPH stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Lord Abbett & CO. LLC, Victory Capital Management Inc., Hellman Jordan Management Co. Inc. MA, Sivik Global Healthcare LLC, Prudential PLC, BlackRock Inc. and Marsico Capital Management LLC. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Cabot Brown, Catherine J Mackey, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello and Volker Knappertz. View Insider Buying and Selling for GW Pharmaceuticals PLC-. Which major investors are buying GW Pharmaceuticals PLC- stock? GWPH stock was purchased by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, ETF Managers Group LLC, Millennium Management LLC, Jennison Associates LLC, Bank of New York Mellon Corp, Sphera Funds Management LTD., River & Mercantile Asset Management LLP and Polar Capital LLP. View Insider Buying and Selling for GW Pharmaceuticals PLC-. How do I buy shares of GW Pharmaceuticals PLC-? Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GW Pharmaceuticals PLC-'s stock price today? One share of GWPH stock can currently be purchased for approximately $168.83. How big of a company is GW Pharmaceuticals PLC-? GW Pharmaceuticals PLC- has a market capitalization of $5.09 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-295,160,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. What is GW Pharmaceuticals PLC-'s official website? The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com. How can I contact GW Pharmaceuticals PLC-? GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected] MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 566 (Vote Outperform)Underperform Votes: 312 (Vote Underperform)Total Votes: 878MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: How is a buy-side analyst different from a sell-side analyst?